Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Loncastuximab Tesirine in Combination With BEAM (Carmustine, Etoposide, Ara-C, Melphalan) Conditioning Regimen Prior to Autologous Stem Cell Transplant (ASCT) and for Maintenance Therapy in Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05228249 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT05228249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05228249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Loncastuximab Tesirine in Combination With BEAM (Carmustine, Etoposide, Ara-C, Melphalan) Conditioning Regimen Prior to Autologous Stem Cell Transplant (ASCT) and for Maintenance Therapy in Diffuse Large B-Cell Lymphoma (DLBCL)
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 1
Overall status
Withdrawn
Start date
April 30, 2023
Completion date
October 1, 2027
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent diffuse large b-cell lymphoma, recurrent diffuse large b-cell lymphoma, not otherwise specified, recurrent high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, recurrent primary mediastinal (thymic) large b-cell lymphoma, recurrent transformed follicular lymphoma to diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma, not otherwise specified, refractory high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, refractory primary mediastinal (thymic) large b-cell lymphoma, refractory transformed follicular lymphoma to diffuse large b-cell lymphoma